The Daily Fuckup

Businesses do not need a tariff policy they love. They need one they can model. The trouble with the current import fight is that the rules keep arriving with layers, exceptions and staggered dates that make pricing and sourcing harder than they already are.

The latest pharmaceutical move came on April 2, 2026, when the White House issued a proclamation imposing a 100% duty on patented pharmaceuticals and associated ingredients. But the headline rate is only part of the story. The same action sets a 20% rate for products from companies with approved onshoring plans, a 15% rate for certain products from the European Union, Japan, South Korea, and Switzerland and Liechtenstein, and a lower United Kingdom rate tied to a future deal. Companies that have executed or are negotiating qualifying pricing and production agreements can get no tariff at all. Generic drugs and biosimilars are left out for now. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2026/04/adjusting-imports-of-pharmaceuticals-and-pharmaceutical-ingredients-into-the-united-states/))

The timing is just as fragmented. The White House says the 100% tariff will take effect in 120 days for some large companies and 180 days for smaller companies, while the 20% onshoring rate is set to climb to 100% four years after the proclamation date. That is a policy with a clock, but not a simple one. Different product categories and company profiles face different treatment, which makes it harder for importers, manufacturers and distributors to set a single assumption and stick with it. ([whitehouse.gov](https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-bolsters-national-security-and-strengthens-u-s-supply-chains-by-imposing-tariffs-on-patented-pharmaceutical-products/))

That kind of setup is manageable only in the narrowest sense. A firm can prepare for a known duty. It can raise prices, shift suppliers or build more inventory. What gets expensive is uncertainty about which bucket a product will land in and when a given rate will actually bite. Procurement teams end up building plans around classification fights, waiver eligibility and whether a product will be covered by one of the carveouts. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2026/04/adjusting-imports-of-pharmaceuticals-and-pharmaceutical-ingredients-into-the-united-states/))

The capital-spending problem is even uglier. A company thinking about a new plant or a new production line has to guess whether the tariff structure will still look the same by the time that project comes online. If the answer is no, the investment calculus changes. The result is often slower hiring, more cautious inventories and longer decision cycles, even before any duty is collected. The tariff is the headline. The churn around it is the drag. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2026/04/adjusting-imports-of-pharmaceuticals-and-pharmaceutical-ingredients-into-the-united-states/))

Pharmaceuticals make that especially clear because the government is trying to force more domestic production while still keeping the door open for negotiated relief. The proclamation and fact sheet both make onshoring and pricing deals part of the policy architecture. That may be useful leverage. It is also a way of telling companies that the real cost of importing is not just the rate on paper, but the chance that the rate changes after the next round of talks. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2026/04/adjusting-imports-of-pharmaceuticals-and-pharmaceutical-ingredients-into-the-united-states/))

The broader message is hard to miss. Tariffs are being used less like a one-time intervention than like a rolling pressure campaign, with separate schedules for separate categories and a standing invitation to negotiate. For the administration, that looks like leverage. For businesses, it looks like a moving target. And when the target keeps moving, the default response is to slow decisions, pad inventories and treat each new announcement as another risk to manage. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2026/04/adjusting-imports-of-pharmaceuticals-and-pharmaceutical-ingredients-into-the-united-states/))